Located in Rockville The clinical-stage biopharmaceutical business MacroGenics, Inc. (Nasdaq: MGNX), which is creating novel antibody-based cancer treatments, announced that Eric Risser has been appointed President, Chief Executive Officer, and to the Board of Directors as of August 13, 2025.
According to MacroGenics, Mr. Risser has been the company’s chief operating officer since 2022. He has been in charge of a number of important business operations and has spearheaded the corporate development initiatives of the company, which have produced more than $1.6 billion in non-dilutive capital since its founding. After 24 years as President and CEO, Scott Koenig, M.D., Ph.D., is stepping down and will be replaced by Mr. Risser.
According to MacroGenics Chair Bill Heiden, Eric is a highly strategic leader with than 30 years of expertise in the biotech and pharmaceutical industries. He has a proven track record of creating value, managing a portfolio effectively, and negotiating innovative deals. The Board and I am excited to work with Eric to realize his compelling vision for MacroGenics.
I would like to express our profound thanks to Scott for his many years of service on behalf of Eric, the Board, the Company’s employees, and everyone else with whom Scott has collaborated relentlessly since the Company’s inception. The company saw numerous triumphs under his direction, including the creation of three medications that have now received FDA approval. Mr. Heiden continued by saying that Scott will remain available to the company as a director and advisor.
“I would like to express my gratitude to the Board for their trust in my ability to guide MacroGenics into its next phase,” Mr. Risser said. My objective is to build a biotechnology business that is even more targeted and capital-efficient and that provides patients with cancer with innovative, high-value treatments. To make sure MacroGenics is allocating resources where we think we can provide substantial value for patients and shareholders alike, I will be collaborating closely with the Board and the entire executive team.
Since joining MacroGenics in 2009 to spearhead the company’s business development initiatives, Mr. Risser has taken on positions with progressively greater operational and strategic accountability, most recently serving as Chief Operating Officer. Mr. Risser was a Senior Director in Corporate Development at Johnson & Johnson before joining MacroGenics, where he oversaw several licensing and acquisition deals. He worked in investment banking, venture capital, and strategy consulting in a range of life science positions earlier in his career. Mr. Risser graduated from Yale University with a B.A. and Stanford University with an M.B.A.
